Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Clinical Development in Multiple Sclerosis Diagnosis and Treatment
share announcement

Clinical Development in Multiple Sclerosis Diagnosis and Treatment

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 4329

Special Issue Editor

Dr. Majid Ghareghani

E-Mail Website
Guest Editor
Neuroscience Laboratory, CHU de Québec Research Center, Department of Molecular Medicine, Faculty of Medicine, Laval University, Québec City, QC, Canada
Interests: multiple sclerosis; melatonin; neural stem cells; Alzheimer's disease; neuroinflammation; biomarker

Special Issue Information

Dear Colleagues,

Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease that continues to challenge clinicians and researchers alike. Recent years have seen a surge in our understanding of the pathogenesis and treatment options for MS, yet there is still much to be uncovered. The application of humoral, clinical, or digital biomarkers to detect early onset or monitor disease progression has become commonplace. A biomarker precisely reflecting the inflammatory and degenerative components of MS would allow for therapies to be exactly adapted, reducing delays in treatment optimization. The call for robust molecular and cellular biomarkers to evaluate MS therapies is more urgent than ever.

This Special Issue focuses on enhancing our understanding and advancing the field of MS through innovative research on biomarkers. We are inviting original research articles and reviews that explore:

  • Pharmacogenomics and Proteomics in MS: Studies investigating the influence of genetic variations and protein functions on MS drug response and safety.
  • Systems Biology in MS: Research that provides a holistic view on MS pathogenesis, including the interactions among biological systems and their role in disease onset, progression, and therapy.
  • Omics Association Analysis in MS: Papers that use genomics, transcriptomics, proteomics, and metabolomics to identify potential biomarkers for MS diagnosis, prognosis, and therapeutic response.
  • Clinical Development of MS Biomarkers: Contributions detailing the rigorous clinical testing and validation of biomarkers, demonstrating their reliability, validity, and clinical utility in MS.

We also warmly welcome any related papers that are not listed above.

In this era of precision medicine, the discovery and clinical implementation of reliable biomarkers can dramatically improve the diagnosis and treatment of MS. We look forward to your contributions and believe that together we can ignite new discussions and insights, and help shape the future of MS research and clinical practice.

Dr. Majid Ghareghani
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • multiple sclerosis
  • biomarker
  • proteomics
  • omics

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Review

3 pages, 150 KiB  
Editorial
Multiple Sclerosis Research Evolves: A Closer Look at Deep Gray Matter, Sexual Function Rehabilitation, and T Regulatory Cells
by Majid Ghareghani and Serge Rivest
J. Pers. Med. 2024, 14(2), 202; https://doi.org/10.3390/jpm14020202 - 12 Feb 2024
Viewed by 735
Abstract
Multiple sclerosis (MS) is a chronic autoimmune condition that leads to the loss of myelin and, subsequently, neuronal damage in the central nervous system (CNS) [...] Full article
(This article belongs to the Special Issue Clinical Development in Multiple Sclerosis Diagnosis and Treatment)

Research

Jump to: Editorial, Review

10 pages, 246 KiB  
Article
Supervised Pelvic Floor Muscle Training Improves Sexual Function and Diminishes Sexual Distress in Women with Relapsing–Remitting Multiple Sclerosis: A Randomised Controlled Study
by Athanasios Zachariou, Athanasios Zikopoulos, Vaia Sapouna, Chara Skentou, Aris Kaltsas, Ioannis Giannakis, Dimitrios Zachariou, Fotios Dimitriadis, Charalampos Mamoulakis, Dung Ba Tien Mai, Nguyen Ho Vinh Phuoc, Atsushi Takenaka and Nikolaos Sofikitis
J. Pers. Med. 2024, 14(1), 88; https://doi.org/10.3390/jpm14010088 - 12 Jan 2024
Cited by 2 | Viewed by 1133
Abstract
This study investigates the impact of pelvic floor muscle training (PFMT) on sexual function and distress in women with multiple sclerosis (MS), a prevalent chronic nervous system disorder associated with sexual dysfunction. This study’s primary aim was to assess the effectiveness of PFMT [...] Read more.
This study investigates the impact of pelvic floor muscle training (PFMT) on sexual function and distress in women with multiple sclerosis (MS), a prevalent chronic nervous system disorder associated with sexual dysfunction. This study’s primary aim was to assess the effectiveness of PFMT at improving sexual function and alleviating sexual distress in this population. In a randomised controlled trial, 82 women with MS were divided into two groups: Group A (41 women) underwent 12 weeks of PFMT, while Group B (41 women) served as a control group with no intervention. Both groups were assessed at the beginning and end of this study using the Female Sexual Function Index (FSFI) and Female Sexual Distress Scale-Revised (FSDS-R). Statistical analysis, including Chi-square tests, was employed to compare the outcomes between the two groups, with a p-value of less than 0.05 considered significant. The results revealed no significant differences in baseline sexual function and distress between the groups. However, at the conclusion of the 12-week period, Group A exhibited statistically significant improvements in nearly all domains of FSFI and FSDS-R compared to Group B, except in the pain domain. This study concludes that PFMT can effectively enhance sexual function and reduce sexual distress in women suffering from MS. These findings underscore the potential of PFMT as a therapeutic intervention in managing sexual dysfunction associated with MS. Full article
(This article belongs to the Special Issue Clinical Development in Multiple Sclerosis Diagnosis and Treatment)
►▼ Show Figures

Graphical abstract

14 pages, 4496 KiB  
Article
Multimodal Investigation of Deep Gray Matter Nucleus in Patients with Multiple Sclerosis and Their Clinical Correlations: A Multivariate Pattern Analysis Study
by Feiyue Yin, Zichun Yan, Yongmei Li, Shuang Ding, Xiaohua Wang, Zhuowei Shi, Jinzhou Feng, Silin Du, Zeyun Tan and Chun Zeng
J. Pers. Med. 2023, 13(10), 1488; https://doi.org/10.3390/jpm13101488 - 12 Oct 2023
Cited by 1 | Viewed by 968
Abstract
Deep gray matter (DGM) nucleus are involved in patients with multiple sclerosis (MS) and are strongly associated with clinical symptoms. We used machine learning approach to further explore microstructural alterations in DGM of MS patients. One hundred and fifteen MS patients and seventy-one [...] Read more.
Deep gray matter (DGM) nucleus are involved in patients with multiple sclerosis (MS) and are strongly associated with clinical symptoms. We used machine learning approach to further explore microstructural alterations in DGM of MS patients. One hundred and fifteen MS patients and seventy-one healthy controls (HC) underwent brain MRI. The fractional anisotropy (FA), mean diffusivity (MD), quantitative susceptibility value (QSV) and volumes of the caudate nucleus (CN), putamen (PT), globus pallidus (GP), and thalamus (TH) were measured. Multivariate pattern analysis, based on a machine-learning algorithm, was applied to investigate the most damaged regions. Partial correlation analysis was used to investigate the correlation between MRI quantitative metrics and clinical neurological scores. The area under the curve of FA-based classification model was 0.83, while they were 0.93 for MD and 0.81 for QSV. The Montreal cognitive assessment scores were correlated with the volume of the DGM and the expanded disability status scale scores were correlated with the MD of the GP and PT. The study results indicated that MS patients had involvement of DGM with the CN being the most affected. The atrophy of DGM in MS patients mainly affected cognitive function and the microstructural damage of DGM was mainly correlated with clinical disability. Full article
(This article belongs to the Special Issue Clinical Development in Multiple Sclerosis Diagnosis and Treatment)
►▼ Show Figures

Figure 1

Review

Jump to: Editorial, Research

29 pages, 844 KiB  
Review
Regulatory T Cells in Multiple Sclerosis Diagnostics—What Do We Know So Far?
by Borros Arneth
J. Pers. Med. 2024, 14(1), 29; https://doi.org/10.3390/jpm14010029 - 25 Dec 2023
Cited by 1 | Viewed by 1055
Abstract
Background: Multiple sclerosis (MS) is an autoimmune disorder that affects the central nervous system (CNS) through inflammation. MS symptoms become acute if the disease progresses to the relapsing phase. Aim: This review aimed to evaluate the role played by regulatory T cells (Tregs) [...] Read more.
Background: Multiple sclerosis (MS) is an autoimmune disorder that affects the central nervous system (CNS) through inflammation. MS symptoms become acute if the disease progresses to the relapsing phase. Aim: This review aimed to evaluate the role played by regulatory T cells (Tregs) in the pathogenesis of MS. Methods: This review used scholarly journal articles obtained from PubMed, PsycINFO, and CINAHL with different search parameters such as ‘regulatory T cells’, ‘multiple sclerosis’, and ‘current knowledge’. The process of searching for articles was limited to those that had publication dates falling between 2010 and 2020. Results: Tregs play a role in the pathogenesis of MS. This conclusion is supported by animal disease models and environmental factors that can underlie Treg alterations in MS. Despite the knowledge of the role played by Tregs in MS pathogenesis, the specific subsets of Tregs involved in MS development remain incompletely understood. Discussion: This review provides an essential link between Tregs and MS activity. Targeting Tregs could be an efficient way to establish new treatment methods for MS management. Conclusion: MS is a complex condition affecting many people worldwide. Research has shown that Tregs can influence MS development and progression. More investigations are needed to understand how Tregs affect the pathogenesis of MS. Full article
(This article belongs to the Special Issue Clinical Development in Multiple Sclerosis Diagnosis and Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop